A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.
ProPublica's deep-dive into Medicare brand-prescribing habits show brands make a dent in Medicare's budget.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
The proposed change would allow generics makers to update labels even if branded drugmakers do not, possibly opening up generics to new liability issues.
Researchers say it's not just payers supporting the switch, and all ages appear to be brand agnostic.
The governor says it is too early to legislate on drugs the FDA is still deliberating over.
The agency says the copycat antidepressant failed to meet bioequivalency requirements.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
The generics maker says it may take five years for its iteration of the GSK asthma/COPD brand to hit the market.
The regulator says serial filers and time restraints are draining resources and staff.
The advisory panel endorsed the treatment with an 11-2 vote.
FDA draft guidance for generic Advair hits GSK's stock; US looks into GSK's China conduct; Roche invests in cancer and hep. B research; Biogen inks a Parkinson's partnership; Forest names former B&L chief as CEO
Biogen extend Isis relationship for six years and $100M; HHS readies healthcare reform TV push; Medivir ends hep. B clinical trial; FDA approves Celgene cancer drug; Baxter seeks Enbrel biosimilar
FDA is concerned state biosimilar legislation could make consumers uneasy about the category, J&J hands $75 million milestone payment for ibrutinib, Consumer Reports gets into drug apps
The positive way to frame the companies' quarterly results: "less bad," as generics continued to plague their balance sheets.
Glaxo shakes up China division, Teva and Lonza break up their biosimilars pact, and FDA's breakthrough designation speeds review but not international and payer uptake.
Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
The drug maker can now add five new doses to its generic Opana ER offerings.
Amgen pays $50 million for a cardio collaboration, and Wockhardt gets locked out of the EU.
Eli Lilly and Boehringer Ingelheim submit a glargine biosimilar to the EMA; Novartis pipeline claims an Enbrel-superior treatment; Activartis med gets orphan drug status; generics makers may have to pay more attention to labels; Administration tweaks healthcare reform implementation over the long weekend.
Indian health regulators recently banned Takeda's Actos, a perplexing move that could set a new precedent in the country.
CHMP recommended two Remicade biosimilars for approval. Its nod comes with an added shakeup: the European agency sanctioned the copies for indications beyond RA.
Researchers quantify the rate at which doctors, nurses and pharmacists buy off-label OTC drugs.
A JAMA article says prostate cancer patients are getting treatments they don't need; Roche and AstraZeneca will share safety data; WellPoint gives cost sharing a new spin; Bayer seeks to boost its oncology pipeline; Takeda announces organizational changes; and the FDA puts Allergan's Restasis on track for generic competition.
The drug maker says it expects to use the Phase III clinical trial data to back applications in the EU and the US (when it gets a pathway setup).
For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.
The Supreme Court split the baby on "pay-for-delay" settlements, allowing them to continue but opening manufacturers that make them up to lawsuits.
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
The effectiveness of new drugs is in decline, says an analysis, and researchers say comparative studies should look beyond efficacy measures.
AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters.